Have a personal or library account? Click to login
GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge Cover

GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge

Biuletyn Głównej Biblioteki Lekarskiej
Volume 58 (2025): Issue 385 (December 2025)
By: Marta Grycan,  Gabriela Grycan and  Michał Pstrągowski  
Open Access
|Dec 2025

References

  1. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21. doi: 10.1111/dom.13129. PMID: 29364588.
    Open DOISearch in Google ScholarBack to article
  2. Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Aug;24(8):631-650. doi: 10.1038/s41573-025-01183-8. Epub 2025 Apr 25. Erratum in: Nat Rev Drug Discov. 2025 Jul;24(7):570. doi: 10.1038/s41573-025-01231-3. PMID: 40281304.
    Open DOISearch in Google ScholarBack to article
  3. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013 Jun 4;17(6):819-837. doi: 10.1016/j.cmet.2013.04.008. Epub 2013 May 16. PMID: 23684623.
    Open DOISearch in Google ScholarBack to article
  4. Farr OM, Li CR, Mantzoros CS. Central nervous system regulation of eating: Insights from human brain imaging. Metabolism. 2016 May;65(5):699-713. doi: 10.1016/j.metabol.2016.02.002. Epub 2016 Feb 6. PMID: 27085777; PMCID: PMC4834455.
    Open DOISearch in Google ScholarBack to article
  5. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11- 22. doi: 10.1056/NEJMoa1411892. PMID: 26132939.
    Open DOISearch in Google ScholarBack to article
  6. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989- 1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
    Open DOISearch in Google ScholarBack to article
  7. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. PMID: 31189511.
    Open DOISearch in Google ScholarBack to article
  8. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. PMID: 27295427; PMCID: PMC4985288.
    Open DOISearch in Google ScholarBack to article
  9. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
    Open DOISearch in Google ScholarBack to article
  10. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
    Open DOISearch in Google ScholarBack to article
  11. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. PMID: 37366315.
    Open DOISearch in Google ScholarBack to article
  12. Drugs.com. Retatrutide FDA approval status. Accessed February 2024. Available from: https://www. drugs.com/history/retatrutide.html.
    Search in Google ScholarBack to article
  13. Amazing-Meds. Is Retatrutide FDA approved? Accessed June 2025. Available from: https://www.amazing-meds.com/is-retatrutide-fda-approved.
    Search in Google ScholarBack to article
  14. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. PMID: 30473097; PMCID: PMC6308032.
    Open DOISearch in Google ScholarBack to article
  15. Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4. PMID: 30293770.
    Open DOISearch in Google ScholarBack to article
  16. Yabe D, Kawamori D, Seino Y, Oura T, Takeuchi M. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy). Diabetes Obes Metab. 2023 Feb;25(2):398-406. doi: 10.1111/dom.14882. Epub 2022 Nov 2. PMID: 36184780; PMCID: PMC10092154.
    Open DOISearch in Google ScholarBack to article
  17. Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15. PMID: 33325008; PMCID: PMC7843845.
    Open DOISearch in Google ScholarBack to article
  18. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
    Open DOISearch in Google ScholarBack to article
  19. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. doi: 10.1016/S2213- 8587(21)00203-5. Epub 2021 Aug 20. PMID: 34425083.
    Open DOISearch in Google ScholarBack to article
  20. Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021 Aug;9(8):525-544. doi: 10.1016/S2213-8587(21)00113-3. Epub 2021 Jun 25. PMID: 34181914.
    Open DOISearch in Google ScholarBack to article
  21. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. doi: 10.1016/S2213- 8587(21)00203-5. Epub 2021 Aug 20. PMID: 34425083.
    Open DOISearch in Google ScholarBack to article
DOI: https://doi.org/10.2478/bgbl-2025-0015 | Journal eISSN: 2956-6851 | Journal ISSN: 0373-174X
Journal RSS Feed
Language: English
Page range: 15 - 32
Accepted on: Aug 19, 2025
Published on: Dec 10, 2025
Published by: The Medical Library named after S. Konopka in Warsaw
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
obesity,
GLP-1,
GIP,
tirzepatide,
semaglutide,
pharmacological treatment
Related subjects:
Medicine,
Biomedical engineering

© 2025 Marta Grycan, Gabriela Grycan, Michał Pstrągowski, published by The Medical Library named after S. Konopka in Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 58 (2025): Issue 385 (December 2025)Next article